Survey - Il Regolamento - Aiot - Associazione Italiana Oncologia Toracica

1)Are you:

Medical oncologist

Radiation oncologist

Thoracic surgeon

2)In which region do you practice:

North-west (Valle d’Aosta, Piemonte, Liguria, Lombardia)

North-east (Trentino Alto-Adige, Veneto, Friuli-Venezia Giulia, Emilia-Romagna)

Center (Umbria, Lazio, Toscana, Marche)

South (Campania, Abruzzo, Molise, Basilicata, Puglia, Calabria)

Isles (Sicilia, Sardegna)

3)Your facility has:

(select the option that best describes)

General oncology program (oncologists treating all cancer types)

Distinct thoracic oncology program (equipe dedicated to thoracic tumors)

4)Has your facility a Lung Multidisciplinary Tumor Board (MTB)?

yes (if yes, proceed to question 5, 6, 7)

no (if no, proceed to question 8)

5)If yes to question 4., how often does the MTB meet?

weekly

every 2 weeks

monthly

other (i.e., upon specific request)

6)How many cases are discussed in a typical MTB at your facility:

(provide median number)

<10

10-20

21-30

31-40

>40

7)Which cases are discussed in your MTB?

All patients with thoracic cancer diagnosis

Peculiar cases at specialist’s discretion

Mainly surgical cases

Mainly metastatic cases

mainly locally advanced (stage III) cases

8)If answer to question 4. is no, how do you manage the flow of a patient with lung cancer?

Flow is guided by indications of each specialist, sequentially

Flow is guided by family doctor

Flow is guided by the first specialist (whichever) who see the patient

9)Which is the usual approach for molecular testing at your facility in early-stage/locally advanced NSCLC cases:

Reflex

On MTB or specialist request

10) Which is the usually applied molecular testing at your facility in early-stage/locally advanced NSCLC cases:

(select all that apply)

PD-L1

EGFR

ALK

NGS

other

11)Which % stage II NSCLC receive indication for upfront surgery at your facility?

<30%

30-60%

61-80%

>80%

12)Which % stage III (N0-N1) NSCLC receive indication for upfront surgery at your facility?

<30%

30-60%

61-80%

>80%

13)Which % stage III (N2) NSCLC receive indication for upfront surgery at your facility?

<30%

30-60%

61-80%

>80%

14)Which % stage III (N2) NSCLC receive indication for surgery after induction treatment at your facility?

<30%

30-60%

61-80%

>80%

15)In which % oncologists change the indication to upfront surgery into induction treatment in NSCLC at your facility?

10%

11-30%

31-50%

>50%

16)In which % radiation oncologists change the surgical indication into definitive CT-RT in NSCLC at your facility?

10%

11-30%

31-50%

>50%

17)In your opinion, the willing to use perioperative immunotherapy according to Oncologist, applies to:

All stage I-III NSCLC (EGFR, ALK wt)

All stage II-III NSCLC (EGFR, ALK wt)

Stage III NSCLC (EGFR, ALK wt)

Selected NSCLC cases

18)In your opinion, the willing to use perioperative immunotherapy according to Thoracic Surgeon, applies to:

All stage I-III NSCLC (EGFR, ALK wt)

All stage II-III NSCLC (EGFR, ALK wt)

Stage III NSCLC (EGFR, ALK wt)

Selected NSCLC cases

19) Dichiarazione

Dichiaro e autocertifico sotto la mia responsabilità di appartenere alla classe medica, consapevole delle conseguenze penali previste in caso di dichiarazioni mendaci.

State of the art in the approach to early-stage and locally advanced NSCLC patients in Italy .

DALLA BACHECA

Pubblicazione "Incorporating atezolizumab in the adjuvant setting of 2 non-small cell lung cancer (NSCLC): key discussion points from an 3 expert multidisciplinary panel by Italian Association of Thoracic Oncology - AIOT"

29/06/2022

Survey sullo stato dell'arte nell'approccio italiano ai pazienti negli stadi precoci e localmemte avanzati del NSCLC

Disponibile dal 01 Agosto 2024 al 30 Settembre 2024

Diventa socio AIOT, entra e compila il form di registrazione.